Ki-67-directed antisense therapy in an orthotopic renal cell carcinoma model

European Urology

Volumn 46, Issue 1, 2004, Pages 118-125

  Kausch, I ^a   Jiang, H ^b   Brocks, C ^a   Bruderek, K ^a   Kruger S ^a   Sczakiel, G ^a   Jocham, D ^a   Bohle A ^c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b ZHEJIANG UNIVERSITY   (China)

^c HELIOS AGNES KARLL HOSPITAL   (Germany)

Author keywords

Antisense; Ki 67; Molecular therapy; Proliferation; Renal cell cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CATION; CD31 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; KI 67 ANTIGEN; LIPID; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHOROTHIOIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; KIDNEY CAPSULE; KIDNEY CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TRANSPORT; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 2942585393     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.03.016     Document Type: Article

References (22)

1. B. Delahunt P.B. Bethwaite A. Thornton J.L. Ribas Proliferation of renal cell carinoma assessed by fixation-resistant polyclonal Ki-67 labeling Cancer 75 1995 2714 2719
2. N. Rioux-Leclercq B. Turlin J.Y. Bansard J.J. Patard A. Manunta J.P. Moulinoux Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma Urology 55 2000 501 505
3. H. Visapaä M. Bui Y. Huang D. Seligson H. Tsai A. Pantuck Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma Urology 61 2003 845 850
4. I. Kausch A. Lingnau E. Endl K. Sellmann I. Deinert T.L. Ratliff Antisense treatment against the Ki-67-mRNA inhibits proliferation and tumor growth in vitro and in vivo Int. J. Cancer 105 2003 710 716
5. T. Scholzen J. Gerdes The Ki-67 protein: from the known and the unknown J. Cell Physiol. 182 2000 311 322
6. E. Endl J. Gerdes The Ki-67 protein: fascinating forms and an unknown function Exp. Cell Res. 257 2000 231 237
7. E. Endl J. Gerdes Posttranslational modifications of the Ki-67 protein coincide with two major checkpoints during mitosis J. Cell Physiol. 182 2000 371 380
8. D.E. MacCallum P.A. Hall Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding Exp. Cell Res. 252 1999 186 198
9. T. Scholzen E. Endl C. Wohlenberg S. van Der Sar I.G. Cowell J. Gerdes The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher-order chromatin structure J. Pathol. 196 2002 135 144
10. S.R. Cooper J.K. Taylor L.J. Miraglia N.M. Dean Pharmacology of antisense oligonucleotide inhibitors of protein expression Pharmacol. Ther. 82 1999 427 435
11. I. Kausch A. Böhle Antisense oligonucleotide therapy in urology J. Urol. 168 2002 239 247
12. F.N. Plenat B.M. Klein-Monhoven J.M. Vignaud A. Duprez Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing mice Am. J. Path. 147 1995 124 125
13. A.A. Levin A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides Biochimica et Biophysica Acta 1489 1999 69 83
14. J. Drevs I. Hofmann H. Hugenschmidt C. Wittig H. Madjar M. Müller Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model Cancer Res. 60 2000 4819 4824
15. G.G. Hillman J. Droz G.H. Haas Experimental animal models for the study of therapeutic approaches in renal cell carcinoma In Vivo 8 1994 77 80
16. L.J. Scherer J.J. Rossi Approaches for the sequence-specific knockdown of mRNA Nature Biotechnol. 21 2003 1457 1465
17. J. Folkman M. Klagsbrun A family of angiogenic peptides Nature 329 1987 671 672
18. M. Hilker M. Buerke H.A. Lehr H. Oelert U. Hake Bypass graft disease: analysis of proliferative activity in human aorto-coronary bypass grafts Heart Surg. Forum S5 2002 331 341
19. M.E. Gleave T. Zellweger K. Chi H. Miyake S. Kiyama L. July Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer Invest. New Drugs 20 2 2002 145 158 Review
20. M. Gleave H. Miyake U. Zangemeister-Wittke B. Jansen Antisense therapy: current status in prostate cancer and other malignancies Cancer Metastasis Rev. 21 1 2002 79 92
21. I.E. Eder J. Hoffmann H. Rogatsch G. Schafer D. Zopf G. Bartsch Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor Cancer Gene Ther. 9 2 2002 117 125
22. N.M. Dean C.F. Bennett Antisense oligonucleotide-based therapeutics for cancer Oncogene 22 2003 9087 9096